ArcherDX and UCL Present New Minimal Residual Disease Surveillance Data from their Collaboration at 2020 AACR Virtual Annual Meeting https://archerdx.com/archerdx-and-ucl-present-new-minimal-residual-disease-surveillance-data-from-their-collaboration-at-2020-aacr-virtual-annual-meeting/

ArcherDX and UCL Present New Minimal Residual Disease Surveillance Data from their Collaboration at 2020 AACR Virtual Annual Meeting First presentation of the data utilizing […]
ArcherDX and Premier Inc. Partner to Deliver Personalized Genomic Testing to Patients https://archerdx.com/archerdx-and-premier-inc-partner-to-deliver-personalized-genomic-testing-to-patients/

ArcherDX and Premier Inc. Partner to Deliver Personalized Genomic Testing to Patients STRATAFIDE™ Proprietary Test Designed to Enable Community Hospitals to Rapidly Deliver Accurate and […]
Letter from Chief Executive Officer and Co-founder, Jason Myers https://archerdx.com/letter-from-chief-executive-officer-and-co-founder-jason-myers/

Letter from Chief Executive Officer and Co-founder, Jason Myers April 17, 2020 Over the course of the last several weeks, our lives have been disrupted […]
ArcherDX and UCL to Present Data from their Collaboration at the 2020 AACR Virtual Annual Meeting https://archerdx.com/archerdx-and-ucl-to-present-data-from-their-collaboration-at-the-2020-aacr-virtual-annual-meeting/

ArcherDX and UCL to Present Data from their Collaboration at the 2020 AACR Virtual Annual Meeting BOULDER, Colo., April 15, 2020 /PRNewswire/ — ArcherDX, Inc., […]
ArcherDX Receives Approval for Archer®MET Companion Diagnostic for TEPMETKO® (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan https://archerdx.com/archerdx-receives-approval-for-archermet-companion-diagnostic-for-tepmetko-tepotinib-in-advanced-non-small-cell-lung-cancer-in-japan/

ArcherDX Receives Approval for Archer®MET Companion Diagnostic for TEPMETKO® (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan BOULDER, Colo., March 25, 2020/PRNewswire/ — ArcherDX, […]
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device https://archerdx.com/archerdx-personalized-cancer-monitoring-pcm-technology-designated-by-fda-as-breakthrough-device/

ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, […]
ArcherDX to Present at 38th Annual J.P. Morgan Healthcare Conference https://archerdx.com/archerdx-to-present-at-38th-annual-j-p-morgan-healthcare-conference/

ArcherDX to Present at 38th Annual J.P. Morgan Healthcare Conference BOULDER, Colo., Jan. 8, 2020 /PRNewswire/ — ArcherDX, Inc., a molecular diagnostics company dedicated to […]
ArcherDX Appoints Mark Massaro Chief Financial Officer https://archerdx.com/archerdx-appoints-mark-massaro-chief-financial-officer/

ArcherDX Appoints Mark Massaro Chief Financial Officer BOULDER, Colo., Jan. 7, 2020 /PRNewswire/ — ArcherDX, Inc., a molecular diagnostics company developing breakthrough solutions to advance […]
ArcherDX Announces Close of $55 Million Series C Financing https://archerdx.com/archerdx-announces-close-of-55-million-series-c-financing/

ArcherDX Announces Close of $55 Million Series C Financing Proceeds to Support Registration and Launch of STRATAFIDE™ Pan-Solid Tumor Companion Diagnostic (CDx) and Development of […]
ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests https://archerdx.com/archerdx-announces-partnership-with-illumina-to-develop-in-vitro-diagnostic-tests/

ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests Partnership Expands Physician Access to Clinical Testing that May be Performed in Local Laboratories for […]